[Edaily] C&R Research led US FDA approval of ‘EYELEA’ Phase 3 IND clinical trial
C&R Research successfully carried out US FDA approval for the Phase 3 IND clinical trial of ‘EYELEA’ Biosimilar with Rophibio, Inc.
This is the first visible achievement of C&R Research, which has been providing services for Pre-IND and IND approval to the FDA since establishing its U.S. branch at the end of last year. C&R Research plans to not only help domestic pharmaceutical bio companies obtain IND approval from the FDA, but also provide IND services to small and medium-sized pharmaceutical bio companies in the United States.
